Leerink Partnrs Has Weak Outlook for AxoGen FY2028 Earnings

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Investment analysts at Leerink Partnrs cut their FY2028 EPS estimates for AxoGen in a report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will earn $0.12 per share for the year, down from their previous estimate of $0.13. The consensus estimate for AxoGen's current full-year earnings is ($0.33) per share.

AxoGen (NASDAQ:AXGN - Get Free Report) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. The business had revenue of $47.91 million during the quarter, compared to analysts' expectations of $43.27 million.

A number of other equities analysts have also recently commented on AXGN. Raymond James began coverage on shares of AxoGen in a research note on Monday, July 1st. They issued an "outperform" rating and a $13.00 price target for the company. Canaccord Genuity Group reissued a "buy" rating and issued a $15.00 target price on shares of AxoGen in a research note on Thursday, June 20th. StockNews.com upgraded AxoGen from a "hold" rating to a "buy" rating in a research report on Tuesday. Finally, JMP Securities upped their price objective on AxoGen from $17.00 to $20.00 and gave the stock a "market outperform" rating in a report on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $15.00.

AxoGen Price Performance

Shares of NASDAQ AXGN traded down $0.08 during midday trading on Friday, hitting $13.16. 267,920 shares of the company's stock were exchanged, compared to its average volume of 400,954. The company has a current ratio of 3.51, a quick ratio of 2.32 and a debt-to-equity ratio of 0.70. The business's fifty day moving average price is $13.31 and its two-hundred day moving average price is $9.44. The company has a market cap of $575.16 million, a price-to-earnings ratio of -26.32 and a beta of 1.13. AxoGen has a 12-month low of $3.45 and a 12-month high of $15.23.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its holdings in AxoGen by 2,014.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider's stock valued at $9,490,000 after buying an additional 1,248,823 shares during the last quarter. Divisadero Street Capital Management LP raised its stake in shares of AxoGen by 587.2% during the second quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider's stock valued at $4,974,000 after acquiring an additional 587,024 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of AxoGen by 26.8% during the second quarter. Rice Hall James & Associates LLC now owns 194,269 shares of the medical equipment provider's stock worth $1,407,000 after purchasing an additional 41,095 shares during the period. Lazard Asset Management LLC grew its stake in shares of AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider's stock worth $93,000 after purchasing an additional 2,671 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in AxoGen by 8.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider's stock valued at $240,000 after purchasing an additional 2,204 shares during the period. Hedge funds and other institutional investors own 80.29% of the company's stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.